Summary by Moomoo AI
On November 6, 2024, bluebird bio, Inc., a biotechnology company focused on gene therapies, announced the partial adjournment of its annual stockholders' meeting to solicit additional votes for Proposal 4, which involves a reverse stock split. The meeting, which took place on the same day, saw the approval of Proposals 1, 2, 5, 6, and 7, while Proposal 3 was not approved. The adjourned meeting is scheduled to reconvene on December 4, 2024, to address Proposal 4 exclusively. This proposal seeks to amend the company's certificate of incorporation to allow a reverse stock split at a ratio between 1-for-15 and 1-for-20, as determined by the board of directors. CEO Andrew Obenshain cited the risk of delisting from Nasdaq due to the current stock price and the need for additional capital to...Show More
